Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial.

Trial Profile

Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms VINODAT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Nov 2013 Results published in the American Journal of Transplantation.
    • 11 Sep 2013 Primary endpoint 'Glycaemic-control' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top